Share on StockTwits

Shares of Charles River Laboratories (NYSE:CRL) have been given a consensus rating of “Hold” by the thirteen analysts that are covering the stock, ARN reports. Eight investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $58.00.

In other Charles River Laboratories news, Director George Massaro sold 10,440 shares of Charles River Laboratories stock in a transaction that occurred on Tuesday, August 26th. The shares were sold at an average price of $60.00, for a total value of $626,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

A number of research firms have recently commented on CRL. Analysts at Deutsche Bank reiterated a “hold” rating on shares of Charles River Laboratories in a research note on Wednesday, August 13th. They now have a $59.00 price target on the stock, up previously from $58.00. Separately, analysts at Credit Suisse reiterated a “neutral” rating on shares of Charles River Laboratories in a research note on Friday, August 8th. They now have a $60.00 price target on the stock, up previously from $56.00. Finally, analysts at SunTrust initiated coverage on shares of Charles River Laboratories in a research note on Tuesday, June 24th. They set a “neutral” rating and a $55.00 price target on the stock.

Charles River Laboratories (NYSE:CRL) opened at 59.10 on Wednesday. Charles River Laboratories has a 52 week low of $44.12 and a 52 week high of $62.50. The stock has a 50-day moving average of $56.06 and a 200-day moving average of $56.2. The company has a market cap of $2.759 billion and a P/E ratio of 24.50.

Charles River Laboratories (NYSE:CRL) last released its earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.15. The company had revenue of $341.18 million for the quarter, compared to the consensus estimate of $327.96 million. During the same quarter in the previous year, the company posted $0.73 earnings per share. The company’s revenue for the quarter was up 16.5% on a year-over-year basis. Analysts expect that Charles River Laboratories will post $3.33 EPS for the current fiscal year.

Charles River Laboratories International, Inc is a global provider of solutions, which accelerate the early-stage drug discovery and development process.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.